Shots:

• The EC’s approval is based on P-III EXPAND study assessing Mayzent vs PBO in patients with SPMS with active disease defined as patients with relapses in the two years prior to the study and/or presence of Gd-enhancing T1 lesions at baseline
• Results in patients with active disease & in overall population: reduction in three‑month and six‑month CDP (31% and 37% & 21% and 26%) respectively; 79% reduction in T2 lesion volume; 55% reduction in ARR; patients free from Gd enhancing lesions (89% vs 67%); from T2 lesions (57% vs 37%)
• Mayzent is a sphingosine 1-phosphate receptor modulator- selectively targeting S1P1 and S1P5 receptors and has received the US FDA’s & TGA’s approval in Mar & Nov’2019 respectively

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Business today